| Year |
Citation |
Score |
| 2020 |
McFeely SJ, Ritchie TK, Yu J, Nordmark A, Berglund EG, Levy RH, Ragueneau-Majlessi I. Inhibitors of Organic Anion-Transporting Polypeptides 1B1 and 1B3: Clinical Relevance and Regulatory Perspective. Journal of Clinical Pharmacology. PMID 32196692 DOI: 10.1002/Jcph.1604 |
0.346 |
|
| 2020 |
Yu J, Ragueneau-Majlessi I. In vitro-to-in vivo Extrapolation of Transporter Inhibition Data for Drugs Approved by the U.S. Food and Drug Administration in 2018. Clinical and Translational Science. PMID 31981398 DOI: 10.1111/Cts.12750 |
0.349 |
|
| 2020 |
Yu J, Petrie I, Ragueneau-Majlessi I. P87 - Main mechanisms of pharmacokinetic drug-drug interactions triggering label recommendations for drugs approved by the food and drug administration in 2018 Drug Metabolism and Pharmacokinetics. 35. DOI: 10.1016/J.Dmpk.2020.04.088 |
0.313 |
|
| 2019 |
McFeely SJ, Yu J, Zhao P, Hershenson S, Kern S, Ragueneau-Majlessi I, Hartman D. Drug-Drug Interactions of Infectious Disease Treatments in Low Income Countries: A Neglected Topic? Clinical Pharmacology and Therapeutics. PMID 30771252 DOI: 10.1002/Cpt.1397 |
0.312 |
|
| 2019 |
McFeely SJ, Ritchie TK, Yu J, Nordmark A, Levy RH, Ragueneau-Majlessi I. Identification and Evaluation of Clinical Substrates of Organic Anion Transporting Polypeptides 1B1 and 1B3. Clinical and Translational Science. PMID 30706983 DOI: 10.1111/Cts.12623 |
0.344 |
|
| 2018 |
Yu J, Petrie ID, Levy RH, Ragueneau-Majlessi I. Mechanisms and Clinical Significance of Pharmacokinetic-based Drug-drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 30442649 DOI: 10.1124/Dmd.118.084905 |
0.35 |
|
| 2018 |
Yu J, Zhou Z, Tay-Sontheimer J, Levy RH, Ragueneau-Majlessi I. Risk of Clinically Relevant Pharmacokinetic-based Drug-drug Interactions with Drugs Approved by the U.S. Food and Drug Administration Between 2013 and 2016. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 29572333 DOI: 10.1124/Dmd.117.078691 |
0.358 |
|
| 2018 |
Yu J, Ragueneau-Majlessi I. Understanding the risk of clinically significant pharmacokinetic-based drug–drug interactions with drugs newly approved by the US FDA – A review of recent new drug applications (2013–2016) Drug Metabolism and Pharmacokinetics. 33. DOI: 10.1016/J.Dmpk.2017.11.163 |
0.311 |
|
| 2017 |
Yu J, Zhou Z, Tay-Sontheimer J, Levy RH, Ragueneau-Majlessi I. Intestinal Drug Interactions Mediated by OATPs: A Systematic Review of Pre-clinical and Clinical Findings. Journal of Pharmaceutical Sciences. PMID 28414144 DOI: 10.1016/J.Xphs.2017.04.004 |
0.357 |
|
| 2016 |
Yu J, Zhou Z, Owens KH, Ritchie TK, Ragueneau-Majlessi I. What Can Be Learned from Recent New Drug Applications? A Systematic Review of Drug Interaction Data for Drugs Approved by the U.S. FDA in 2015. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 27821435 DOI: 10.1124/Dmd.116.073411 |
0.381 |
|
| 2015 |
Yu J, Ritchie TK, Zhou Z, Ragueneau-Majlessi I. Key Findings from Preclinical and Clinical Drug Interaction Studies Presented In New Drug and Biological License Applications Approved by the FDA in 2014. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 26424199 DOI: 10.1124/Dmd.115.066720 |
0.362 |
|
| 2014 |
Yu J, Ritchie TK, Mulgaonkar A, Ragueneau-Majlessi I. Drug disposition and drug-drug interaction data in 2013 FDA new drug applications: a systematic review. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 42: 1991-2001. PMID 25271211 DOI: 10.1124/Dmd.114.060392 |
0.346 |
|
| 2013 |
Ai X, Wu Y, Zhang W, Zhang Z, Jin G, Zhao J, Yu J, Lin Y, Zhang W, Liang H, Datta PK, Zhang M, Zhang B, Chen X. Targeting the ERK pathway reduces liver metastasis of Smad4-inactivated colorectal cancer. Cancer Biology & Therapy. 14: 1059-67. PMID 24025354 DOI: 10.4161/Cbt.26427 |
0.416 |
|
| 2009 |
Mora-Pale M, Weïwer M, Yu J, Linhardt RJ, Dordick JS. Inhibition of human vascular NADPH oxidase by apocynin derived oligophenols. Bioorganic & Medicinal Chemistry. 17: 5146-52. PMID 19523836 DOI: 10.1016/J.Bmc.2009.05.061 |
0.612 |
|
| 2008 |
Yu J, Weïwer M, Linhardt RJ, Dordick JS. The role of the methoxyphenol apocynin, a vascular NADPH oxidase inhibitor, as a chemopreventative agent in the potential treatment of cardiovascular diseases. Current Vascular Pharmacology. 6: 204-17. PMID 18673160 DOI: 10.2174/157016108784911984 |
0.609 |
|
| Show low-probability matches. |